Research programme: antibacterials - Aviragen Therapeutics

Drug Profile

Research programme: antibacterials - Aviragen Therapeutics

Alternative Names: Benzothiazole urea based inhibitors - Aviragen Therapeutics; CDI-538 series antibacterials - Prolysis; CDI-936 series antibacterials - Prolysis; GYR-767 series antibacterials - Prolysis; PC-190708; PC-190723

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Prolysis
  • Developer Aviragen Therapeutics
  • Class 2 ring heterocyclic compounds; Amides; Small molecules
  • Mechanism of Action Cell division inhibitors; DNA gyrase inhibitors; DNA topoisomerase IV inhibitors; Mitosis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Bacterial infections; Clostridium infections; Pneumonia; Skin and soft tissue infections; Staphylococcal infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Bacterial-infections in Australia (IV)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Bacterial-infections in Australia (PO)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Clostridium-infections in Australia (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top